pargyline has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 1 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A novel unsymmetrical structural class of orally bioavailable hepatitis C virus (HCV) nonstructural 5A protein (NS5A) inhibitors has been generated by improving both the solubility and membrane permeability of the lead compound found in our previous work." | 1.56 | Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class. ( Akagi, Y; Fujioka, S; Inaba, T; Ito, S; Kinoshita, W; Komoda, Y; Kondo, K; Maeda, K; Nakamura, H; Okuda, S; Tamatani, Y; Terui, T; Ukaji, Y, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, H | 1 |
| Fujioka, S | 1 |
| Terui, T | 1 |
| Okuda, S | 1 |
| Kondo, K | 1 |
| Tamatani, Y | 1 |
| Akagi, Y | 1 |
| Komoda, Y | 1 |
| Kinoshita, W | 1 |
| Ito, S | 1 |
| Maeda, K | 1 |
| Ukaji, Y | 1 |
| Inaba, T | 1 |
1 other study available for pargyline and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.
Topics: Administration, Oral; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Mutation; Pargyl | 2020 |